<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03814031</url>
  </required_header>
  <id_info>
    <org_study_id>12156</org_study_id>
    <nct_id>NCT03814031</nct_id>
  </id_info>
  <brief_title>Hepatic Vein Flow During Orthotopic Liver Transplantation as Predictive Factor for Postoperative Graft Function</brief_title>
  <official_title>Hepatic Vein Flow Assessment With Transesophageal Echocardiography for Postoperative Graft Function Prediction in Orthotopic Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic vein flow (HVF) assessment using transesophageal echocardiography (TEE) has a
      potential to predict postoperative graft function in orthotopic liver transplant (OLT).
      Investigators will measure HVF using TEE and assess the correlation with postoperative graft
      function indices such as prolonged total bilirubin level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During OLT, intraoperative TEE assessment of HVF (systolic and diastolic), and indices of
      postoperative graft function including time to normalization of INR, platelet, and total
      bilirubin. HVF was calculated with hepatic vein area (cm2) x hepatic vein velocity (ml/s) in
      systole and diastole during the neohepatic phase. Investigators defined HVF index (HVFi) as:
      HVF/donor liver size (kg). Investigators did ROC analysis to assess the predictive power for
      prolonged INR, platelet, and total bilirubin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Anticipated">December 3, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prolonged total bilirubin &gt;7 days</measure>
    <time_frame>7 days status post OLT</time_frame>
    <description>We will follow total bilirubin after OLT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>early graft loss</measure>
    <time_frame>6 weeks status post OLT</time_frame>
    <description>graft loss within 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late graft loss</measure>
    <time_frame>6 weeks status post OLT</time_frame>
    <description>graft loss after more than 6 weeks</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Postoperative Graft Function</condition>
  <arm_group>
    <arm_group_label>postoperative prolonged total bilirubin</arm_group_label>
    <description>We will follow total bilirubin treat after orthotopic liver transplant, and include in this ARM if prolonged total bilirubin &gt;7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>postoperative NOT prolonged total bilirubin</arm_group_label>
    <description>We will follow total bilirubin treat after orthotopic liver transplant, and include in this ARM if prolonged total bilirubin &lt;7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NO internvention</intervention_name>
    <description>NO internvention</description>
    <arm_group_label>postoperative NOT prolonged total bilirubin</arm_group_label>
    <arm_group_label>postoperative prolonged total bilirubin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        OLT with piggy back technique
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Orthotopic liver transplants which uses TEE intraoperatively Must be Piggy back technique -

        Exclusion Criteria:

        TEE absolute contraindication patient refusal

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yoshihisa Morita, MD</last_name>
    <phone>313-970-1282</phone>
    <email>ymorita1@hfhs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmad Itani, DO</last_name>
    <phone>313-704-8451</phone>
    <email>aitani1@hfhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HFHS</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jones</last_name>
      <phone>313-874-4420</phone>
      <email>kjones1@hfhs.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 16, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Yoshihisa Morita</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>TEE</keyword>
  <keyword>orthotopic liver transplant</keyword>
  <keyword>postoperative graft function</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

